Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment

Harvard Review of Psychiatry

Volumn 17, Issue 2, 2009, Pages 138-146

  Kenna, Heather A ^a   Jiang, Bowen ^a   Rasgon, Natalie L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Dyslipidemia; Menstrual abnormalities; Metabolic dysfunction; Obesity; PCOS

Indexed keywords

AGOUTI RELATED PROTEIN; ARIPIPRAZOLE; CARBAMAZEPINE; CARNITINE; CLOZAPINE; ESTRONE; GHRELIN; LAMOTRIGINE; LITHIUM; NEUROPEPTIDE Y; OLANZAPINE; OREXIN; OXCARBAZEPINE; PROGESTERONE; QUETIAPINE; RISPERIDONE; TESTOSTERONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE; ZONISAMIDE; LEPTIN; LITHIUM CARBONATE; PSYCHOTROPIC AGENT;

ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARNITINE DEFICIENCY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE FUNCTION; EPILEPSY; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; MOOD DISORDER; MORBIDITY; NEUROENDOCRINE DISEASE; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WAIST HIP RATIO; WEIGHT GAIN; DRUG EFFECT; ENDOCRINE DISEASE; FEMALE; HYPOGONADISM; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENSTRUATION; METABOLISM; PATHOPHYSIOLOGY;

BIPOLAR DISORDER; DYSLIPIDEMIAS; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPOGONADISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LEPTIN; LITHIUM CARBONATE; MENSTRUATION; OBESITY; PITUITARY-ADRENAL SYSTEM; POLYCYSTIC OVARY SYNDROME; PSYCHOTROPIC DRUGS; VALPROIC ACID;

EID: 68549085250     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220902899722     Document Type: Review

References (85)

1. Newberg A, Catapano L, Zarate C, Manji H. Neurobiology of bipolar disorder. Expert Rev Neurother 2008;8:93-110.
2. Rothschild A. Biology of depression. Med Clin North Am 1988;72:765-790
3. Rasgon N, Altshuler L, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000;61:173-178
4. Rasgon N, Altshuler L, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005;7:246-259 (Pubitemid 40778887)
5. Rasgon N, Bauer M, Glenn T, Elman S, Whybrow P. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord 2003;5:48-52.
6. O'Donovan C, Kusumaker V, Gravess G, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-330
7. McIntyre R, Mancini D, McCann S, Srinivasan J, Kennedy S. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28-35.
8. Akdeniz F, Taneli F, Noyan A, Ÿunc̈u Z, Vahip S. Valproateassociated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatry 2003;27:115-121
9. Rasgon N, ReynoldsM, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005;89:217-235
10. Joffe H, Cohen L, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59:1078-1086
11. Joffe H, Kim D, Foris JB, et al. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. J Clin Psychiatry 2006;67:297-304.
12. Newcomer J. Antipsychotic medications; metabolic and cardiovascular risk. J Clin Psychiatry 2007;68 suppl 4:8-13.
13. Masand P, Culpepper L, Henderson D, et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005;10(10 suppl 14):1-15. (Pubitemid 41531972)
14. Lofgren E, Tapanainen J, Koivunen R, Pakarinen A, Isojarvi J. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia 2006;47:1441-1446
15. Banning M. Symptoms and treatments of polycystic ovary syndrome. Br J Nurs 2006;15:635-639
16. Reynolds M, Sisk E, Rasgon N. Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. Curr Med Chem 2007;14:2799-2812
17. Burt V, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004;6:2-13.
18. Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Jpn J Psychiatry Neurol 1993;47:825-842
19. Isojarvi J, Laatikainen T, Pakarinen A, Juntunen KM, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388
20. Isojarvi J, Rattya J, Myllyla V, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. AnnNeurol 1998;43:446-451
21. O'Donovan C, Kusumakar V, Graves G, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-330
22. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of noninsulin- dependent diabetes mellitus. Am J Med 1995;98:33s- 39s.
23. Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008;64:200-211
24. Fagiolini A, Chengappa KN. Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep 2007;9:521-528
25. Elmslie JL, Silverstone JT, Mann JI,Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000;61:179-184
26. Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J 1999;92:898-904.
27. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord 2008;110:149-155
28. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006;67:1034-1041
29. Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000;61 suppl 9:35-40.
30. Peselow ED, Dunner DL, Fieve RR, Lautin A. Lithium carbonate and weight gain. J Affect Disord 1980;2:303-310
31. Bowden C, Calabrese J, McElroy S. A randomized, placebocontrolled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-489
32. Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in longterm treatment. Acta Psychiatr Scand 1980;62:193-200.
33. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003;64 suppl 8:22-29
34. Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry 1995;28:35-44.
35. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J Psychopharmacol 2006;20:347-355
36. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988;78:434-441
37. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976;53:139-147
38. Mathew B, Rao J Sundari U. Lithium-induced changes in body mass index. Acta Psychiatr Scand 1976;53:355-359
39. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002;27:104-107
40. Levine S, Saltzman A. Lithium increases gastrointestinal tract weight of male or female rats but it increases body weight only in females. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:29-33.
41. van der Velde C, Gordon M. Manic-depressive illness, diabetes mellitus, and lithium carbonate. Arch Gen Psychiatry 1969;21:478-485
42. Mellerup ET, Thomsen HG, Bjorum N, Rafaelsen OJ. Lithium, weight gain, and serum insulin in manic-depressive patients. Acta Psychiatr Scand 1972;48:332-336
43. Vendsborg PB, Rafaelsen OJ. Lithium in man: effect on glucose tolerance and serum electrolytes. Acta Psychiatr Scand 1973;49:601-610
44. Vieweg WV, Godleski LS, Hundley PL, Yank GR. Lithium, polyuria and abnormal diurnal weight gain in psychosis. Acta Psychiatr Scand 1988;78:510-514
45. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-670
46. Garland EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 1998;12:385-395
47. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-978
48. El-Khatib F, RauchenzaunerM, Lechleitner M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007;16:226-232
49. Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatographymass spectrometry. Clin Chim Acta 1985;145:69-76.
50. Laub MC. [Hyperammonemia in valproate therapy in children and adolescents]. Nervenarzt 1986;57:314-318
51. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi J. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-517
52. Stephen L, Kwan P, Shapiro D, Dominiczak M, Brodie M. Hormone profiles in young adultswith epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-1006
53. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-118
54. Joffe RT, Post RM, Uhde TW. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986;47:313-314
55. Khanna V, Arumugam S, Roy S, Mittra S, Bansal VS. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 2008;12:81-90.
56. Tata AL, Kockler DR. Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother 2006;40:1993-1997
57. Post RM, Altshuler LL, Frye MA, et al. New findings from the Bipolar Collaborative Network: clinical implications for therapeutics. Curr Psychiatry Rep 2006;8:489-497
58. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs 2005;19 suppl 1:1-93.
59. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486-91; quiz 492-493
60. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008;10:342-348
61. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-430
62. Garcia-Portilla M, Saiz P, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008;106:197-201.
63. Jakovljevic M, Reiner Z, Milicic D. Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub 2007;19:270-281
64. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359
65. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247-252
66. Cardenas J, FryeMA, Marusak SL, et al.Modal subcomponents of metabolic syndrome in patientswith bipolar disorder. J Affect Disord 2008;106:91-97
67. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330-336
68. Luef G, Lechleitner M, Bauer G, Trinka E, Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:53-58
69. Isojarvi J, Laatikainen T, Knip M, Pakarinen A, Juntunen K, Myllyla V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584
70. Tsai SY, Lee HC, Chen CC. Hyperinsulinaemia associated with beta-adrenoceptor antagonist in medicated bipolar patients during manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1038-1043
71. Cassidy F, Ritchie J, Carroll B. Plasma dexamethasone concentration and cortisol response during manic episodes. Biol Psychiatry 1998;43:747-754
72. Brindley DN, Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci (Lond) 1989;77:453-461
73. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997;46:717-719
74. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996;20: 291-302.
75. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194
76. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008;28: 132-137
77. Gergerlioglu HS, Savas HA, Celik A, et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology 2006;53:108-112
78. Olfson M, Marcus SC, Wilk J, West JC. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv 2006;57:205-211
79. Baptista T, Kin N, Beaulieu S, de Baptista E. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-219
80. Rubi B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2- like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005;280:36824-36832
81. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005;68 suppl 1:S60-4.
82. Theisen FM, Gebhardt S, Bromel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005;112:1411-1416
83. Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004;172:230-232 (Pubitemid 38388774)
84. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005;44:925-933
85. Wu R, Zhao J, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized clinical trial. JAMA 2008;299:185-193